Partition behavior of CD133+ stem cells from human umbilical cord blood in aqueous two‐phase systems: In route to establish novel stem cell primary recovery strategies

Biotechnology Progress - Tập 30 Số 3 - Trang 700-707 - 2014
Mirna González‐González1, Marco Rito‐Palomares1, Olivia Méndez Quintero2
1Centro de Biotecnología‐FEMSA Tecnológico de Monterrey Campus Monterrey, Ave. Eugenio Garza Sada 2501 Sur Monterrey NL 64849 México
2Hospital Metropolitano “Dr. Bernardo Sepúlveda” Ave. López Mateos 4600 San Nicolás de los Garza NL 66480 México

Tóm tắt

Aqueous two‐phase systems (ATPS) represent a promising strategy for the recovery of CD133+ stem cells. This particular type of stem cells has great potential for research and clinical applications. Traditional [polyethylene glycol (PEG), dextran (DEX), and ficoll] and novel (Ucon) polymer–polymer ATPS were exploited to study the partitioning behavior of CD133+ stem cells and contaminants from human umbilical cord blood (HUCB). The aim of the study was to select conditions under which the product of interest and the contaminants concentrate in opposite phases. To accomplish this, three independent samples were tested: (1) enriched CD133+ sample, (2) whole HUCB (contaminants), and (3) complex sample (CD133+ stem cells and contaminants). The objective of this research was to evaluate the partition behavior of CD133+ in ATPS in route to establish the basis for the development of a novel and scalable purification bioprocess. In conclusion, the partitioning behavior of CD133+ stem cells and contaminants from complex samples was as follows: 59% of CD133+ stem cells fractionated to the top phase when employing ficoll 400,000–DEX 70,000 or 100% to the bottom phase with Ucon‐DEX 75,000 and PEG 8,000‐DEX 500,000 ATPS. In average, 35% of the contaminants partitioned to the top phase of the ficoll 400,000‐DEX 70,000 ATPS, 99% to the dextran rich phase of the Ucon‐DEX 75,000 systems and 97% to the bottom phase of the PEG 8,000‐DEX 500,000. Cell viability was at least 98% after ATPS recovery. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 30:700–707, 2014

Từ khóa


Tài liệu tham khảo

10.1002/jctb.2723

10.1002/ceat.200800068

10.1016/j.jchromb.2004.01.008

10.2741/e265

Ahmadi H, 2012, Five‐Year follow‐up of the local autologous transplantation of CD133+ enriched bone marrow cells in patients with myocardial infarction, Arch Iran Med., 15, 32

Nikeghbalian S, 2011, Autologous transplantation of bone marrow‐derived mononuclear and CD133 + cells in patients with decompensated cirrhosis, Arch Iran Med., 14, 12

10.1155/2011/385124

10.1089/scd.2010.0373

Klein HM, 2010, Intraoperative CD133+ cell transplantation during coronary artery bypass grafting in ischemic cardiomyopathy, Multimed Man Cardiothorac Surg., 2010, 1

10.1002/clc.20463

10.1016/j.bbmt.2007.07.004

10.1016/j.jtcvs.2006.08.077

10.1080/14653240600735909

10.1016/j.exphem.2005.03.004

10.1046/j.1365-2141.2003.04747.x

10.1038/sj.leu.2403563

10.1038/sj.bmt.1703558

10.1182/blood.V90.12.5013

10.1517/14712598.2010.528386

10.1182/blood.V90.12.5002

Peichev M, 2000, Expression of VEGFR‐2 and AC133 by circulating human CD34 + cells identifies a population of functional endothelial precursors, Blood., 95, 952, 10.1182/blood.V95.3.952.003k27_952_958

10.1073/pnas.97.26.14720

Ma Y, 2002, The expression and functional characteristics of AC133 antigen in cord blood hematopoietic cells, Chin J Intern Med., 41, 798

10.3109/07388551.2013.794125

10.1089/scd.1.1996.5.213

10.1007/s10529-011-0727-0

10.1007/10_2006_043

10.1007/s10544-008-9238-8

González‐González M, 2012, PEGylation, detection and chromatographic purification of site‐specific PEGylated CD133‐Biotin antibody in route to stem cell separation, J Chromatogr B: Anal Technol Biomed Life Sci., 893

Thông tin
Thông tin xuất bản

Biotechnology Progress

Tập 30 Số 3

700-707

Thông tin tác giả